Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up.

31 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders.

3 Jul 2015

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories.

30 Jun 2015

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy.

30 Jun 2015

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer.

25 Jun 2015

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition.

23 Jun 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.

1 Jun 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

Study shows superiority of Cxbladder Detect over other non-invasive bladder cancer diagnostic tool

Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used tests was published online this week in the peer-reviewed Open Access medical journal BioMed Central ("BMC") Medical Research Methodology.

27 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

As many as 12 percent of patients undergoing major, non-cardiac surgery experience an irregular heartbeat called atrial fibrillation.

19 May 2015

Study highlights link between poor sleep quality and impact of severe LUTS in some men

Sleep quality may have an impact on the severity of lower urinary tract symptoms, or LUTS, in some men, according to new research presented during the 110th Annual Scientific Meeting of the American Urological Association.

17 May 2015

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

BioLight receives CE Mark approval for CellDetect bladder cancer test

Telesta submits Biologics License Application for MCNA to FDA

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

Nanoplatform technology that detects early stages of cancer receives U.S. patent

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

BioLight Life Sciences reports operational and financial results for Q1 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Study shows superiority of Cxbladder Detect over other non-invasive bladder cancer diagnostic tool

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

Study highlights link between poor sleep quality and impact of severe LUTS in some men

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in